NBTY donates nearly $500,000 in nutritional bars, vitamins to Oklahoma tornado victims
RONKONKOMA, N.Y. — NBTY, a manufacturer and distributor of vitamins, supplements and sports nutrition, announced last week that it will donate nearly $500,000 of Good ‘n Natural bars, Balance Bars and bottles of children’s gummy vitamins to support tornado relief efforts in Oklahoma.
NBTY’s donation is being made through Oklahoma-based charity Feed The Children, an organization whose mission includes responding during times of disaster to provide emergency supplies for those in need. The NBTY-donated supplies will be used to provide convenient, healthy, on-the-go sustenance for relief workers, emergency responders and impacted families.
"We are so incredibly grateful for the generous donation from NBTY, which will positively help the children and families who’ve been affected by the recent tornadoes in Oklahoma," said Erin Engelke, Feed The Children vice president of communications/PR. "Feed The Children is on the ground supporting these families now, and NBTY’s partnership with us ensures they will receive immediate relief as they begin the rebuilding process."
"Our hearts go out to the families and communities impacted by these devastating tornadoes," said Jeff Schneider, senior vice president of product management at NBTY. "Our wish is that our donation of nutritional bars and children’s vitamins helps to make the next few weeks a little easier for the residents of Oklahoma who were impacted by this tragedy. We are glad to be in a position to help."
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Avion Pharmaceuticals launches new prenatal chewable vitamin
ATLANTA — Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced the launch of Prenate Chewable, a chewable, chocolate-flavored version of the original Prenate prescription prenatal vitamin.
A further example of Avion Pharmaceutical’s ongoing commitment to support the Ob/Gyn community, Prenate Chewable provides an innovative – and tasty – option for women who may prefer an alternative method of taking their medications. The new Prenate Chewable includes taste-masking technology to ensure there is no aftertaste, so the patient will only experience the Dutch chocolate flavor.
"Choices are beneficial for patients who must take a prenatal vitamin daily. Prenate Chewable offers a flavorful alternative that will help women maintain compliance with this critically important regimen," stated Mike Sullivan, vice president of sales and marketing for Avion Pharmaceuticals.
"Avion is dedicated to providing innovation that offers ease of use and ease of adherence. Prenate Chewable offers both. We will continue to introduce products that deliver maximum benefit along the continuum of care in women’s lives," added Avion Pharmaceuticals CEO Mark Pugh. "Understanding women’s health and matching products that deliver positive support will help ensure improved lifestyles for women of all ages and life stages."
Are you a pharmacy technician working in the retail industry? Find our group on Facebook for more stories like this and join the conversation.
Biosimilar bill defeated in Texas
WASHINGTON — Texas has become the latest state to defeat a bill that critics say would limit the reach of knock-off versions of biotech drugs.
Texas’ state legislature defeated Senate Bill 190, which is similar to bills in other states that would make it harder for pharmacists to substitute biosimilars for branded biotech drugs. Similar bills have been defeated in Florida, Arizona, Colorado, Indiana, Maryland, Mississippi, Nevada and Washington. The bills in Virginia and Utah passed, but with sunset clauses that are expected to cause them to expire before biosimilars become available; only the bill in North Dakota passed intact, and five other states are considering them.
"Against great odds, key leadership stood firmly in favor of patient health and cost savings by stopping this legislation right in its tracks," Generic Pharmaceutical Association president and CEO Ralph Neas said. The GPhA, a trade group that represents generic drug makers, cited data from pharmacy benefit manager Express Scripts showing that biosimilar versions of 11 widely used biologics could save the U.S. healthcare system $250 billion between 2014 and 2024.